The European Industrial Hemp Association (EIHA) has announced that both full-spectrum and natural isolate products of its consortium partners can remain for sale in the UK now both applications have passed the key administrative check by the UK Food Standards Agency.
In February 2020, the FSA announced a deadline of March 31 2021 for CBD businesses to submit valid novel food applications to allow the continued sale of CBD products in the UK.
The FSA has confirmed to the EIHA that the applications were considered to be compliant with the administrative requirements. The official validation will be granted upon results of toxicological studies on both CBD and THC1, expected in the coming months.
By granting the pre-validation status, the FSA has recognised the willingness of the hemp sector to evaluate and determine the safety levels of its novel food products.
As a partner of EIHA’s Novel Food Consortium, Elixinol Global’s products are now supported by a valid novel food application.
Executive director and global CEO Oliver Horn said: “The FSA’s response means we can continue to operate on a business-as-usual basis for now, while the toxicological work is being undertaken.
“It removes a short-term risk and will open up new opportunities for customer contracts.”